At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY, discusses the results of an analysis that evaluated the effect of a once-daily 420 mg dose of ibrutinib, a Bruton’s tyrosine kinase inhibitor, on progression-free survival in patients with previously treated chronic lymphocytic leukaemia (CLL) from the phase 3 RESONATE trial.
Evaluating sustained adherence to ibrutinib in previously treated CLL
26th August 2015
Oncology
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now